Drugs / AAV2-sFLT01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01024998 | Jan 2010 → Jul 2014 | age-related macular degeneration, retinal vascular disorder | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV2-sFLT01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01024998 ↗ |
| Action | Inhibit | “the VEGF-neutralising protein sFLT01” PMID 28526489 ↗ May 2017 |
| Modality | Gene therapy (AAV / viral vector) | “an AAV2 vector expressing the VEGF-neutralising protein sFLT01” PMID 28526489 ↗ May 2017 |
| Route | Intravitreal | “Single intravitreal injection to a single eye” NCT01024998 ↗ |